Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
Mibefradil is a calcium antagonist approved for the treatment of hypertension and chronic stable angina pectoris. To investigate the relationship between steady state, trough plasma concentrations and blood pressure response in patients with renal dysfunction, data from a multicenter, multiple-dose mibefradil study were analyzed. Changes in sitting diastolic blood pressure from baseline were linearly related to trough plasma mibefradil concentrations. Renal function did not affect plasma mibefradil concentrations. Consequently, mibefradil dosage adjustment is not required for patients with renal impairment.
Pordy
R
R
Roche Laboratories, Nutley, NJ 07110, USA.
Woittiez
A
A
D001562:Benzimidazoles / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications*; D016014:Linear Models; D020748:Mibefradil; D009543:Nifedipine / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D013764:Tetrahydronaphthalenes / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use
D001562:Benzimidazoles; D002121:Calcium Channel Blockers; D013764:Tetrahydronaphthalenes; D020748:Mibefradil; D009543:Nifedipine